ClinicalTrials.gg

Program

sotatercept

Also written as “Sotatercept”, “Sotatercept 0.3 mg/kg” and “Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg”.

Its studies are mostly in Pulmonary Arterial Hypertension · Anemia · Hypertension, Pulmonary · Multiple Myeloma · beta-Thalassemia, led by 2 companies.

Furthest: phase 4, since May 15, 202626 company-led studies, 8 open or runningNext primary completion: Mar 21, 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck228 open or runningphase 4since May 15, 2026May 22, 2009Mar 21, 2028phase 4 · NCT07899905
Bristol-Myers Squibb40 open or runningphase 2since Sep 3, 2008Sep 3, 2008none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Sep 3, 2008.

  1. May 13, 2021Phase 3 study in Pulmonary Arterial HypertensionMerck · NCT04896008 · 173 enrolled · United States, Australia, Belgium and more
  2. Jun 11, 2021Phase 2 study in Hypertension, PulmonaryMerck · NCT04945460 · 165 enrolled · United States, Belgium, Canada and more
  3. Oct 17, 2022Phase 2 study in Pulmonary Arterial HypertensionMerck · NCT05587712 · 42 planned · United States, Australia, Colombia and more
  4. Apr 5, 2023Phase 3 study in Pulmonary Arterial HypertensionMerck · NCT05818137 · 46 enrolled · Japan
  5. Oct 28, 2024Phase 2 study in Pulmonary Arterial HypertensionMerck · NCT06664801 · 164 enrolled · United States, Argentina, Australia and more
  6. Feb 3, 2025Phase 2 study in Hypertension, PulmonaryMerck · NCT06814145 · 440 enrolled · United States, Belgium, Canada and more
  7. Feb 20, 2025Phase 1 study in HealthyMerck · NCT06843460 · 24 enrolled · China
  8. Apr 7, 2025Phase 2 study in Pulmonary Arterial HypertensionMerck · NCT06925750 · 130 enrolled · United States, Argentina, Australia and more
  9. Apr 9, 2025Phase 1 study in HealthyMerck · NCT06930664 · 146 enrolled · United States
  10. Oct 7, 2025Phase 3 study in Pulmonary Arterial HypertensionMerck · NCT07218029 · 815 enrolled · United States, Argentina, Australia and more
  11. May 15, 2026Phase 4 study in Pulmonary Arterial HypertensionMerck · NCT07600723 · 30 planned · India
  12. Jun 9, 2026Phase 2 study in Pulmonary Arterial HypertensionMerck · NCT07646860 · 6 planned · Japan
  13. Sep 18, 2026Phase 3 study in Hypertension, PulmonaryMerck · NCT07839585 · 352 planned
  14. Oct 21, 2026Phase 4 study in Hypertension, PulmonaryMerck · NCT07899905 · 40 planned

Ahead

  1. Mar 21, 2028Primary completion: phase 4 study in Hypertension, PulmonaryMerck · NCT07899905
  2. Apr 3, 2028Primary completion: phase 4 study in Pulmonary Arterial HypertensionMerck · NCT07600723
  3. Jun 16, 2028Primary completion: phase 2 study in Pulmonary Arterial HypertensionMerck · NCT06925750
  4. Sep 21, 2028Primary completion: phase 2 study in Pulmonary Arterial HypertensionMerck · NCT05587712

TargetBeta

INHBA →read by rule
“Inhibin beta A chain inhibitor”ChEMBL 37, by rule

Other programs on INHBA

ProgramCompanyFurthest phaseStudies
garetosmabruleRegeneron Pharmaceuticalsphase 39

Studies

All 26 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07899905Hypertension, Pulmonary4Not yet recruitingMerckMar 21, 202840
NCT07839585Hypertension, Pulmonary3Not yet recruitingMerckJan 8, 2030352
NCT07646860Pulmonary Arterial Hypertension · Japan2RecruitingMerckMay 24, 20296
NCT07600723Pulmonary Arterial Hypertension · India4RecruitingMerckApr 3, 202830
NCT07218029Pulmonary Arterial Hypertension · United States, Argentina, Australia and more3Active, not recruitingMerckDec 7, 2028815
NCT06930664Healthy · United States1CompletedMerckNov 11, 2025146
NCT06925750Pulmonary Arterial Hypertension · United States, Argentina, Australia and more2Active, not recruitingMerckJun 16, 2028130
NCT06843460Healthy · China1CompletedMerckMay 21, 202424
NCT06814145Hypertension, Pulmonary · United States, Belgium, Canada and more2Active, not recruitingMerckAug 10, 2035440
NCT06664801Pulmonary Arterial Hypertension · United States, Argentina, Australia and more2CompletedMerckNov 20, 2025164
NCT05818137Pulmonary Arterial Hypertension · Japan3CompletedMerckMar 12, 202446
NCT05587712Pulmonary Arterial Hypertension · United States, Australia, Colombia and more2RecruitingMerckSep 21, 202842
NCT04945460Hypertension, Pulmonary · United States, Belgium, Canada and more2CompletedMerckSep 5, 2025165
NCT04896008Pulmonary Arterial Hypertension · United States, Australia, Belgium and more3CompletedMerckJul 26, 2024173
NCT04811092Pulmonary Arterial Hypertension · United States, Argentina, Australia and more3TerminatedMerckApr 3, 2025321
NCT04576988Pulmonary Arterial Hypertension · United States, Argentina, Australia and more3CompletedMerckAug 26, 2022324
NCT03738150Pulmonary Arterial Hypertension · United States2CompletedMerckDec 21, 202121
NCT03496207Pulmonary Arterial Hypertension · United States, Australia, Brazil and more2CompletedMerckMar 9, 2022106
NCT01999582Anemia · Belgium, Germany, Portugal and more2CompletedBristol-Myers SquibbAug 31, 201650
NCT01736683Anemia · United States, France2CompletedMerckApr 30, 201874
NCT01571635beta-Thalassemia · France, Greece, Italy and more2TerminatedBristol-Myers SquibbJul 2, 201546
NCT01284348Anemia2TerminatedMerckSep 21, 201226
NCT01190644Solid Tumors · United States2TerminatedMerckSep 18, 20125
NCT01146574Anemia · United States2CompletedBristol-Myers SquibbMar 7, 201650
NCT00931606Anemia · United States, Russian Federation2TerminatedMerckNov 18, 201030
NCT00747123Multiple Myeloma · Russian Federation2CompletedBristol-Myers SquibbAug 1, 200930

How it is read

Names in the registry

  • “Sotatercept”, 22 entries
  • “Sotatercept 0.3 mg/kg”, 1 entry
  • “Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg”, 1 entry
  • “Sotatercept Autoinjector”, 1 entry
  • “ACE-011”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.